企業プロフィール
Amarin Corporation 株価・ニュース・カタリスト
- ティッカー:
- AMRN
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Ireland and listed in the U
株価パフォーマンス
14.01 USD (-0.43%)
終値
最終更新: 2026年8月17日
303M USD
時価総額
株価変動の要因
As of Aug 17, 2026, AMRN closed down 0.43% at $14.01. No new same-company headline was identified in the current news window.
企業概要
Cardiovascular Pharmaceutical Company
Amarin is a global pharmaceutical company focused on reducing cardiovascular disease burden. Its business is centered on VASCEPA and VAZKEPA, branded icosapent ethyl products supported by clinical evidence and approved by multiple regulatory authorities.
Partnered International Model
Amarin shifted to a fully partnered international commercial strategy, including a long-term license and supply agreement with Recordati for Europe-focused commercialization across 59 countries. This model reduced operating expenses while allowing partners with local expertise to drive pricing, reimbursement, market access, and adoption.
U.S. Branded IPE Presence
In the United States, Amarin continues to maintain a leading branded IPE position despite generic competition. The company's U.S. IPE market share increased to 48% in the second quarter of 2026, while branded VASCEPA prescriptions rose year over year.
Strategic Position
Amarin is best understood as a focused cardiovascular company transitioning from direct global commercialization to a leaner partner-led international model. Its near-term performance depends on international volume growth, stable U.S. branded share, disciplined operating expenses, and positive cash flow generation.
今後のカタリスト
- Near-term commercialization progress in Singapore and South Korea.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。